A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Biopharma shares shake off the pandemic
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Sage advice: psychiatric drug development is tough
As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Upcoming events – Sage targets depression and Biogen aims for lupus
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
